Member Info for Fevertreeman

We're all investors in hre unfortunately, and most at much higher levels -very few invested who arent hugely under water. After 10 years at the helm, and millions of £ of investors monies, Newland's god complex-like assumption that the pharma world would beat a path to his door, obviating the need for any serious (or stress tested) commercial planning and management strengthening ahead of FDA approval created the mess we're currently in. he futher compounded it with wildly optimistic presentation to institutions in the 80p raise and we all know what happened after. The issue is not the technology which clearly works well but the management. As yet, there is no evidence to suggest that Newland has changed , with the hype and hope approach still very much in evidence. Thats what so disappointing - the Board and seemingly Jefferies have been unable to manage him.

As for the directors having skin in the game, thats laughable. Outside of Newland & Griffths, the NEds seem to be a share-owning free zone. They are not invested in the future of the company.

Newland has produced one lousy tiny deal in last 6 months, so pathetically small he couldn't dare release the figures (hiding behind that ol' chestnut of commercial sensitivity). He keeps shooting his mouth off about deals in the offing 'including with a household name' that do nothing for his CEO credibility, whilst he continues to burn through cash. Meantime, he parts company with Jefferies, the only adviser, he had with real US clout!

Tripling of revenues brings in a paltry £ 3m vs ongoing annual losses of c£20m annual losses and only £15m in the bank!!!

So what Newland is suggesting with the figs for 2024 is that NO MAJOR DEALS will be signed which is awful

Clear imo that Jefferies walked -have been itching to do so methinks, since they did the raise at 80p and then Newland stuffed them with the revenue warnings and complete lack of commercial progress. Their reputation took a battering from the institutions they persuaded onboard, and I think they have lost complete faith in Newland & Griffiths. I think they think that this has become close to uninvestible for their institutional universe. Hardly surprising, when newland has not produced any substantive commercial progress since FDA approval, and continues to peddle his hype n hope strategy as per the other week with his online investor presentation to US investors, hyping deals being close with some major players etc etc etc. Only announcement since -Jefferies leaves and air cover provided in form of research RNS to distract

Your post nails why there needs to be boardroom change and soon before Johnson et al burn through all this new discounted funding sorting out yet more issues. Precious little faith in Johnson's CEO capabilities to drive this business to consistent performance and profitability over the long term. Lets hope there is some proper strategic discussions about the management's competence taking place around the board. Johnson and Bundred cannot afford yet another operational disappointment

Clearly Jefferies agree with that blue sky valuation which is why they have exited as soon as they could

Next tick in the box - Bundred has to go and be replaced in the new year. We cant have the 2 Board members most responsible for this shambles still in situ. Johnson's time must come (but not yet), but we do need Bundred to go, and be replaced by an expereinced international plc chairman.

So much for the US strategy to build institutional and customer support! Andrew Newland wtf are you playing at? None of the below would be a massive cause for concern if there was confidence in management and Newland actually had delivered some concrete commercial progress, but he hasnt and so investors should be rightly concerned.

Exhibit 1: Testing lab in US shut down (for cost reasons0, immediately removing any physical presence in the biggest market in the world, and where Newland has spent 10ms of millions of dollars trying to get FDA approval. Genius!

Exhibit 2.: Jefferies a serious US investment house with strong biotech credentials walks away just after the online investor meet with small cap US investors, where yet again Newland hyped newsflow. Now as they are likely to have been on 3 months notice either this was triggered before or alternatively they argued with Newland and got fired. Either way the Board has some explaining to do. Oh and then there's situation that there is no liaison with investors with IR guy gone

Apologies I was including the loan…Bundred seems confident…. But again with him & Johnson, the Chuckle Bros, at the helm, what could possibly go wrong?

Nero strikes again…Jefferies have and had proper credibility with US investors. Newland can try and camouflage with another useless pointless RNS but what’s happened here isn’t that Newland has fired them but odds on Jefferies,concerned with their reputation and tiring of the constant hype from Newland, have resigned the account.

£27m raised.Chairman & CEO responsible for operational/financial debacle. What could possibly go wrong?

Newland just cant keep his mouth shut can he

Newland's inability to either keep his mouth shut or provide accurate guidance without hype continues to be a baleful feature of this company.

1. At Sept's Interims Newland said Results would be in line -THEY WEREN'T INSTEAD WE GOT REVENUE MISS

2. He said headline results from the Company's major clinical studies were expected by year end; NOWHERE TO BE SEEN AND WE'RE BARELY A COUPLE OF WEEKS AWAY FROM YEAR END

The new Chairman had an opportunity to read the riot act to Nero, but we still have the same hope n hype approach to shareholder from Newland. The Board of Directorso seem utterly uninterested in rebuilding credibility & holding Newland to account.

Well Nero is so lacking in self awareness he convinced himself that he could manage everything - look where that has got us!

Totally agree....CFO made a big play about it. Other critical issue is that Bundred resigns and we get a competent plc chairman who can actually kick t5his into shape and hold Johnson's feet to the fire.

The key phrase in your post is "as a new investor". Well good for you, but those of us who have been invested in Newland's business have had to suffer through disappointment after disappointment interspersed with Del Boy this time next month we'll be millionaires -type interviews from Nero. You may not be aware that he did a fund raising at 80 p to institutions post the FDA approval, and within months issued a profits warning creating the strong impression he hads no idea what he was doing. Nothing has changed since apart from the hopeless chairman sneaking out the door , some tiny deals, and shutting down the lab in US which had been pushed as a key plank of their US commercial strategy. international

The lack of NED purchases is scandalous!

Because quite simply, Newland hasn't issued any news that would move the needle for his investor base! Where are the commercial tie-ups we've been led to believe were oven-ready? Where is the positive commercial newsflow that Newland clumsily tried to hype in the US investor call... or is this it? Newland has spent 10 years and millions of pounds of shareholders monies and still hasnt delivered a single commercial contract of real commercial value. That is the problem - the facts run counter to the promises made

Remember that Newland has not delivered a single commercial deal of any magnitutde, and we have had nothing, nicht, nowt in over 6 months since May 25th Artios deal which was so inconsequential as to have no number attached to it. Over to you Andrew!